Abstract
The targeted delivery of cytotoxic agents to prostate cancer cells via selective activation of peptide-linked prodrugs by prostate-specific antigen (PSA) has been previously demonstrated. In our continued efforts to design prodrugs with improved prostate tumor specificity, we developed GABA ← mGly-Ala-Ser-Chg-Gln and glutaryl-Ser-Ala-Ser-Chg-Gln as promoieties with enhanced PSA specificity starting from the known substrate sequence glutaryl-Hyp-Ala-Ser-Chg-Gln. Based on their PSA cleavage rates and resistance to non-PSA-mediated hydrolysis in plasma, GABA ← mGly-Ala-Ser-Chg-Gln and glutaryl-Ser-Ala-Ser-Chg-Gln were selected as optimal promoieties and coupled to doxorubicin (Dox) as PSA-targeted prodrugs, using Ser-Leu linkers. Following 72-h incubations with Dox prodrugs, there was insignificant cytotoxicity in non-PSA-producing DU145 cells. The Dox prodrugs, glutaryl-Hyp-Ala-Ser-Chg-Gln-Ser-Leu-Dox (I), glutaryl-Ser-Ala-Ser-Chg-Gln-Ser-Leu-Dox (II) and GABA ← mGly-Ala-Ser-Chg-Gln-Ser-Leu-Dox (III) demonstrated comparable PSA cleavage rates (t1/2 values <23 min), and were cytotoxic against PSA-producing LNCaP cells with IC50 values of 0.18, 0.27 and 0.082 μM, respectively. To mitigate neprilysin-mediated hydrolysis of the Ser-Leu linker in prodrugs I–III and further improve PSA specificity, 3-aminooxypropionate was incorporated between the promoiety and Dox (prodrug IV). Despite its slower PSA cleavage rate (t1/2 value of 67 min), GABA ← mGly-Ala-Ser-Chg-Gln-NH-O-CH2-C(Me)2C(O)-14-O-Dox (IV) was equipotent (IC50 value of 0.19 μM) to prodrug I at killing PSA-producing LNCaP cells due to its ability to release free Dox through a cyclization activation mechanism. Further metabolism and PK/PD studies will be conducted to evaluate the tumor specificity of the novel Dox prodrugs (II–IV) reported herein.
Similar content being viewed by others
Abbreviations
- AMC:
-
7-amino-4-methylcoumarin
- ACN:
-
acetonitrile
- Alloc-OSu:
-
(N-allylcarbonyloxy)succinimide
- Boc:
-
tert-butyloxycarbonyl
- CDI:
-
carbonyldiimidazole
- Chg:
-
L-cyclohexylglycine
- DBU:
-
1,8-diazabicycloundec-7-ene
- DCM:
-
dichloromethane
- DEA:
-
diethylamine
- DIAD:
-
diisopropyl azodicarboxylate
- DIEA:
-
N,N-diisopropylethylamine
- DMF:
-
dimethylformamide
- DMAP:
-
4-dimethylaminopyridine
- Dox:
-
doxorubicin
- DMSO:
-
dimethyl sulfoxide
- EDC:
-
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
- EDU:
-
1-Ethyl-3-(3-dimethylaminopropyl)urea
- FCC:
-
flash column chromatography
- Fm:
-
fluorenylmethyl
- Fmoc:
-
fluorenylmethoxycarbonyl
- FUDR:
-
floxuridine or 5-fluoro-2’-deoxyuridine
- GABA:
-
γ-aminobutyric acid
- HBTU:
-
O-benzotriazole N,N,N’,N’-tetramethyluronium hexa-fluorophosphate
- HOSu:
-
N-hydroxysuccinimide
- HPLC:
-
high performance liquid chromatography
- HRMS:
-
high-resolution mass spectrometry
- Hyp:
-
trans-4-hydroxy-L-proline
- LC-MS:
-
liquid chromatography-mass spectrometry
- MTT:
-
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- IS:
-
internal standard
- NMP:
-
N-methyl-2-pyrrolidone
- NMR:
-
nuclear magnetic resonance
- PSA:
-
prostate-specific antigen
- PyBOP:
-
(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
- RPMI:
-
Roswell Park Memorial Institute
- TCM:
-
tissue culture medium
- MRM:
-
selected reaction monitoring
- THF:
-
tetrathydrofuran
- TFA:
-
trifluoroacetic acid
- TLC:
-
thin-layer chromatography.
References
Abdullah Chowdhury S, Alam S, Aishwarya R, Miriyala S, Panchatcharam M, Pattillo Christopher B, Orr Anthony W, Sadoshima J, Hill Joseph A, Bhuiyan Md S (2018) Abstract 273: autophagy impairment is associated with defects in mitochondrial bioenergetics in doxorubicin cardiomyopathy. Circ Res 123:A273–A273
Aloysius H, Hu L (2015a) Improving the specificity of the PSA substrate Glutaryl-Hyp-Ala-Ser-Chg-Gln as a promoiety. Chem Biol Drug Des 86:837–848
Aloysius H, Hu L (2015b) Targeted prodrug approaches for hormone refractory prostate cancer. Med Res Rev 35:554–585
Aloysius H, Hu L (2020) Synthesis and evaluation of new peptide-NH-2-fluorobenzyl phosphoramide mustard conjugates as prodrugs activated by prostate specific antigen. Med Chem Res 29. https://doi.org/10.1007/s00044-020-02572-x
Atkinson JM, Siller CS, Gill GH (2008) Tumour endoproteases: the cutting edge of cancer drug delivery? Br J Pharm 153:1344–1352
Ayyıldız SN, Ayyıldız A (2014) PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer. Turk J Urol 40:82–88
Balk SP, Ko Y-J, Bubley GJ (2003) Biology of prostate-specific antigen. J Clin Oncol 21:383–391
Bartlett JJ, Trivedi PC, Pulinilkunnil T (2017) Autophagic dysregulation in doxorubicin cardiomyopathy. J Mol Cell Cardiol 104:1–8
Benchetrit T, Bissery V, Mornon JP, Devault A, Crine P, Roques BP (1988) Primary structure homologies between two zinc metallopeptidases, the neutral endopeptidase 24.11 (“enkephalinase”) and thermolysin, through clustering analysis. Biochemistry 27:592–596
Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL (1991) Measurement of prostrate-specific antigen in serum as a screening test for prostrate cancer. N. Engl J Med 324:1156–1161
Choi KY, Swierczewska M, Lee S, Chen X (2012) Protease-activated drug development. Theranostics 2:156–178
Cotterill IC, Rich JO (2005) Chemoenzymatic synthesis of N-trifluoroacetyl doxorubicin-14-valerate (Valrubicin). Org Process Res Dev 9:818–821
Cotterill IC, Rich JO, Scholten MD, Mozhaeva L, Michels PC (2008) Reversible derivatization to enhance enzymatic synthesis: chemoenzymatic synthesis of doxorubicin-14-fl-esters. Biotechnol Bioeng 101:435–440
DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Wai J, Senderak ET, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Freidinger R, Huff J, Oliff A, Jones RE (2000) A peptide-doxorubicin prodrug activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 6:1248–1252
Denmeade SR, Lou W, Lövgren J, Malm J, Lilja H, Isaacs JT (1997) Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 57:4924–4930
Diamandis E (1995) New diagnostic applications and physiological functions of prostate specific antigen. Scand J Clin Lab Invest 55:105–112
DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, Ciardella M, Doyle-Lindrud S, Goodwin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P, Yao SL (2002a) Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 20:1874–1879
DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, Ciardella M, Doyle-Lindrud S, Goodwin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P, Yao SL (2002b) Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 20:1874–1879
Doan NTQ, Paulsen ES, Sehgal P, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Dionne CA, Christensen SB (2015) Targeting thapsigargin towards tumors. Steroids 97:2–7
Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65:4320–4333
Garsky VM, Lumma PK, Feng DM, Wai J, Ramjit HG, Sardana MK, Oliff A, Jones RE, DeFeo-Jones D, Freidinger RM (2001) The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy. J Med Chem 44:4216–4224
Ge Y, Wu X, Zhang D, Hu L (2009) 3-Aminoxypropionate-based linker system for cyclization activation in prodrug design. Bioorg Med Chem Lett 19:941–944
Hayashi R, Cook GR (2008) Bi(OTf)3-catalyzed 5-exo-trig cyclization via halide activation. Tetrahedron Lett 49:3888–3890
Herschman JD, Smith DS, Catalona WJ (1997) Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology 50:239–243
Hortobagyi GN, Willey J, Rahman Z, Holmes FA, Theriault RL, Buzdar AU (1997) Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 24:S17–65-S17-68
Jiang Y, Hu L (2007) Phenylalanyl-aminocyclophosphamides as model prodrugs for proteolytic activation: synthesis, stability, and stereochemical requirements for enzymatic cleavage. Bioorg Med Chem Lett 17:517–521
Kalled SL, Siva N, Stein H, Reinherz EL (1995) The distribution of CD10 (NEP 24.11, CALLA) in humans and mice is similar in non-lymphoid organs but differs within the hematopoietic system: absence on murine T and B lymphoid progenitors. Eur J Immunol 25:677–687
Keil B (1992) Specificity of Proteolysis. Springer-Verlag, Berlin, Heidelberg
Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H (1990) Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharm Ther 47:219–231
Koleini N, Kardami E (2017) Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget 8:46663–46680
Kwiatkowska A, Couture F, Ait-Mohand S, Desjardins R, Dory YL, Guérin B, Day R (2019) Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug. Sci Rep. 9:2118
Lee J, Huang W, Broering JM, Barron AE, Seo J (2015) Prostate tumor specific peptide–peptoid hybrid prodrugs. Bioorg Med Chem Lett 25:2849–2852
Leinonen J, Zhang. W, Stenman U (1996) Complex formation between PSA isoenzymesand protease inhibitors. J Urol 155:1099–1103
Levesque M, Yu H, D’Costa M, Diamandis E (1995) Prostate specific antigen expression by various tumors. J Clin Lab Anal 9:123–128
McDonald AC, Vira MA, Vidal AC, Gan W, Freedland SJ, Taioli E (2014) Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey. Prostate 74:561–567
Ménez R, Michel S, Muller BH, Bossus M, Ducancel F, Jolivet-Reynaud C, Stura EA (2008) Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody. J Mol Biol 376:1021–1033
Murphy LJ, Corder R, Mallet AI, Turner AJ (1994) Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and C-terminal fragment from big endothelin-1. Br J Pharm 113:137–142
Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL (1995) Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154:407–413
O’Malley KJ, Eisermann K, Pascal LE, Parwani AV, Majima T, Graham L, Hrebinko K, Acquafondata M, Stewart NA, Nelson JB, Yoshimura N, Wang Z (2014) Proteomic analysis of patient tissue reveals PSA protein in the stroma of benign prostatic hyperplasia. Prostate 74:892–900
Oefner C, Roques BP, Fournie-Zaluski M-C, Dale GE (2004) Structural analysis of neprilysin with various specific and potent inhibitors. Acta Crystallogr, Sect D: Biol Crystallogr 60:392–396
Otto A, Bar J, Birkenmeier G (1998) Prostate specific antigen forms complexes with human α2-macroglobulin and binds to the α2-macroglobulin receptor/ldl receptor-related protein. J Urol 159:297–303
Rawlings ND, Barrett AJ (1995) Evolutionary families of metallopeptidases. Meth Enzymol 248:183–228
Rho YS, Kim G, Kim W-J, Park S, Yoo DJ, Kang HS, Chung S-R (2001) Synthesis of new anthracycline derivatives containing acetylsalicylic or palmitic acid moiety. Bull Korean Chem Soc 22:587–592
Rho YS, Ko HK, Kim W-J, Yoo DJ, Wing HS (2000) Total synthesis of a new 7-deoxyidarubicinone derivative through the functionalization of an A-ring side chain. Bull Korean Chem Soc 21:774–778
Rho YS, Park S, Kim W-J, Kim G, Yoo DJ, Kang H-S, Chung S-R (2002) Synthesis of new anthracyline derivatives contaning pyruvic, aspartic, or N-acetylaspartic acid molecule. Synth Commun 32:1961–1975
Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A (1993) Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharm Rev 45:87–146
Sahli S, Stump B, Welti T, Schweizer WB, Diederich F, Blum-Kaelin D, Aebi JD, Böhm H-J (2005) A new class of inhibitors for the metalloprotease neprilysin based on a central imidazole scaffold. Helv Chim Acta 88:707–730
Schulz H, Dale GE, Karimi-Nejad Y, Oefner C (2009) Structure of human endothelin-converting enzyme I complexed with phosphoramidon. J Mol Biol 385:178–187
Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC (2008) Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharm Exp Ther 324:95–102
Singhal S, Singhal J, Nair M, Lacko A, Awasthi Y, Awasthi S (2007) Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol 30:717–725
Tarvainen I, Zimmermann T, Heinonen P, Jäntti MH, Yli-Kauhaluoma J, Talman V, Franzyk H, Tuominen RK, Christensen SB (2020) Missing selectivity of targeted 4β-phorbol prodrugs expected to be potential chemotherapeutics. ACS MedChem Lett 11:671–677
Thong A, Müller D, Feuerstacke C, Mietens A, Stammler A, Middendorff R (2014) Neutral endopeptidase (CD10) is abundantly expressed in the epididymis and localized to a distinct population of epithelial cells-Its relevance for CNP degradation. Mol Cell Endocrinol 382:234–243
van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JCC, Heijn M, Boven E, Hoekman K, Pinedo HM (2002) A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem Pharm 63:897–908
Velazquez EF, Yancovitz M, Pavlick A, Berman R, Shapiro R, Bogunovic D, O’Neill D, Yu YL, Spira J, Christos PJ, Zhou XK, Mazumdar M, Nanus DM, Liebes L, Bhardwaj N, Polsky D, Osman I (2007) Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. J Transl Med 5:2
Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19:670–686
Wong BK, DeFeo-Jones D, Jones RE, Garsky VM, Feng DM, Oliff A, Chiba M, Ellis JD, Lin JH (2001) PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab Dispos 29:313–318
Xu X, Persson HL, Richardson DR (2005) Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharm 68:261–271
Yang Y, Aloysius H, Inoyama D, Chen Y, Hu L (2011) Enzyme-mediated hydrolytic activation of prodrugs. Acta Pharm Sin B 1:143–159
Acknowledgements
We gratefully acknowledge the financial support of grant SNJ‐CCR 700–009 from the State of New Jersey Commission on Cancer Research, a pilot grant from the Gallo Prostate Cancer Center of the Cancer Institute of New Jersey, and grant RSG‐03–004–01‐CDD from the American Cancer Society.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have filed patents on some of the compounds discussed in this paper.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abbreviations for common amino acids are in accordance with IUPAC recommendations
Dedicated to Professor Robert P. Hanzlik on the occasion of his retirement after 49 years of dedicated service on the faculty of the Department of Medicinal Chemistry, University of Kansas School of Pharmacy
Rights and permissions
About this article
Cite this article
Aloysius, H., Hu, L. Synthesis and evaluation of new peptide-linked doxorubicin conjugates as prodrugs activated by prostate-specific antigen. Med Chem Res 29, 1280–1299 (2020). https://doi.org/10.1007/s00044-020-02573-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-020-02573-w